Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Receptor tyrosine kinases in cancer escape from BRAF inhibitors.

Cell research - 1 Jun 2012

Lo Roger S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erlotinib Hydrochloride
Share to Indoles
Share to Melanoma
Share to Quinazolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfonamides

Share to Transplantation, Heterologous

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 22565288
DOI: 10.1038/cr.2012.78
PMCID: PMC3367528

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Receptor tyrosine kinases in cancer escape from BRAF inhibitors.PMID 22565288Read ↗

BRAF inhibitors in clinical oncologySemantic proximity Read ↗

BRAF inhibitors in cancer therapy.Semantic proximity Read ↗

Deja Vu: EGF receptors drive resistance to BRAF inhibitors.Semantic proximity Read ↗

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.Semantic proximity Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

Strategies to overcome resistance to targeted protein kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.